Real-world assessment of clinical outcomes In GIST patients treated with Sunitinib after Imatinib failure. (GEIS-43).
CTOS Congress 2021. Poster.
Phase I trial of OLAratumab plus Trabectedin in Advanced Soft-Tissue Sarcoma patients: OLATRASTS, a Spanish Group for Research on Sarcoma (GEIS) study. (GEIS-58).
CTOS Congress 2021. Oral.
REGISTRI: Regorafenib in first-line of KIT/PDGFR Wild Type metastatic GIST: A collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) Phase II trial. (GEIS-40).
CTOS Congress 2021. Oral.
S. Lacerenza. Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups.
ESMO Congress 2021. E-poster.
J. Martin-Broto. REGISTRI: Regorafenib in first-line of KIT/PDGFR Wild Type Advanced GIST: a Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) Phase II trial.
ESMO Congress 2021. Proffered Paper Session.
J. Martin-Broto. Inflammatory indexes neutrophils/lymphocytes, platelets/lymphocytes and red-cell distribution width (RDW) as prognostic biomarkers in advanced solitary fibrous tumors (SFT) treated with pazopanib: correlative study of GEIS-32 trial.
ASCO 2021.
C. Serrano. A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST) - SeliGIST/GEIS-41 trial.
ASCO 2021.
N. Hindi. Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.(GEIS-76).
ASCO 2021.
C. Marquez, J. Martin-Broto,; F.J. Bautista,; R.D. Beveridge, A. CAÑETE, A. Echebarria; M.E. Llinares, J. Martinez-Garcia; C. Mata, R. Alvarez-Alvarez,; A. Regueiro,; M. Torrent, O. Gallego; J.A. Villegas,; M. Guibelalde,; G. Gutierrez,; A. Muñoz; C. Valverde, L. Gros; E. Carretta, S. Ferrari, E. Palmerini; P. Picci; M.A. Vaz. Prognostic value of PGP as stratification factor for the treatment of patients with non-metastatic extremity high-grade osteosarcoma: a Spanish Society of Pediatric Hematology and Oncology (SEHOP) and Spanish Group for Research on Sarcomas (GEIS) study. (GEIS-33).
CTOS 2020.
Moura DS, Hindi N, Lopez Alvarez M, Sanchez Bustos P, Carrasco Garcia I, Santos Fernandez, Martinez Delgado et al. Immune-checkpoint genesaspredictive biomarkers of trabectedin in advanced soft-tissuesarcoma(STS):a Spanish group for research on sarcomas (GEIS) translational study. (GEIS-38).
CTOS 2020.
J. Martin Broto, N. Hindi, A. Redondo, J.M. Morales, D. Marcilla, C. Valverde, P. Luna, R. Diaz-Beveritge, J. Martinez-Trufero, J.A. Lopez-Martin, V. Martinez, A. Gutierrez, A. Lopez-Pousa. Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS). (GEIS-39.)
CTOS 2020.
J. Martin Broto, N. Hindi, A. Redondo, J.M. Morales, D. Marcilla, C. Valverde, P. Luna, R. Diaz-Beveritge, J. Martinez-Trufero, J.A. Lopez-Martin, V. Martinez, A. Gutierrez, A. Lopez-Pousa. Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS). (GEIS-39.)
ESMO 2020.
Martin G. McCabe, Laura Kirton, Maria Khan, Nicola Fenwick, Uta Dirksen, Nathalie Gaspar, Jukka Kanerva, Thomas Kuehne, Alessandra Longhi, Roberto Luksch, Cristina Mata, Marianne Phillips, Akmal Safwat, Sandra J. Strauss, Kirsten Sundby Hall, Claudia Maria Valverde Morales, Andrew J. Westwood, Mark Winstanley, Jeremy Whelan, Keith Wheatley. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). (GEIS-35.)
ASCO 2020.
Bernadette Brennan, Laura Kirton, Perrine Marec-Berard, Javier Martin -Broto, Hans Gelderblom, Nathalie Gaspar, Sandra J Strauss, Ana Sastre Urgelles, Jennifer Anderton, Valerie Laurence, Jeremy Whelan, Keith Wheatley. Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). (GEIS-34.)
ASCO 2020.
Alessandro Gronchi, Nadia Hindi, Jean-Yves Blay, Andres Redondo, Roberta Sanfilippo, Carlo Morosi, Josefina Cruz Jurado, Pablo Luna Fra, Javier Martinez-Trufero, Claudia Maria Valverde Morales, Jesus Romero, Javier Peinado, Claudia Sangalli, Marie Pierre Sunyach, Cleofe Romagosa, Dominique Ranchère-Vince, Antonio Gutierrez, Paolo De Tos, Javier Martin Broto. Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: An international, prospective, phase II trial in localized myxoid liposarcoma—A collaborative Spanish (GEIS), Italian (ISG) and French (FSG) group study. (GEIS-37.)
ASCO 2020.
David Silva Moura, Nadia Hindi, Maria Lopez-Alvarez, Paloma Sanchez-Bustos, Irene Carrasco-Garcia, Paloma Santos-Fernandez, Paula Martinez-Delgado, Serena Lacerenza, Elena Blanco-Alcaina, Jose Lucinio Mondaza-Hernandez, Antonio Gutierrez, Rosa Maria Alvarez, Magda Cordeiro, Luis Miguel De Sande González, Gloria Marquina, Juana Maria Cano, Josefina Cruz Jurado, Claudia Maria Valverde Morales, Javier Martinez-Trufero, Javier Martin Broto. Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study. (GEIS-38.)
ASCO 2020.
Javier Martin Broto, David Silva Moura, Rafael Ramos, Luca Braglia, Paola Collini, Salvatore L Renne, Cleofe Romagosa, Jean Michel Coindre, Valerie Velasco, Domenico F Merlo, Emanuela Palmerini, Silvia Stacchiotti, Vittorio Quagliuolo, Antonio Lopez-Pousa, Giovanni Grignani, Jean-Yves Blay, Antonella Brunello, Piero Picci, Paolo Giovanni Casali, Alessandro Gronchi. Prognostic role of MRP1 in localized high-risk soft tissue sarcoma (STS): Translational research associated to randomized phase III trial (ISG-STS 1001). (GEIS-25.)
ASCO 2020.
Javier Martin Broto, Nadia Hindi, Andres Redondo, Javier Martinez-Trufero, Silvia Stacchiotti, Emanuela Palmerini, Enrique Alava, David Silva Moura, Herminia Perez Vega, Irene Otero, Patricio Ledesma, Emanuela Marchesi, Jose A. Lopez-Martin. IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—Results of the phase I part. (GEIS-52.)
ASCO 2020.
Javier Martinez-Trufero; Luis Miguel De Sande Gonzalez; Pablo Luna; Javier Martin-Broto; Rosa Alvarez; Antonio Casado; Roberto Diaz Beveridge; Andres Poveda; Juana Maria Cano; Josefina Cruz; Antonio López Pousa; Maria Angeles Vaz Salgado; Claudia M. Valverde Morales; Isabel Sevilla; Jeronimo Martinez; Jordi Rubio Casadevall; Ana De Juan; Juan Antonio Carrasco; Antonio Gutierrez. Validation of GEISTRA score: a predictive tool of Trabectedin (tb) benefit in Advanced Soft Tissue Sarcomas (ASTS), based on Growth Modulation Index (GMI). A retrospective registry-based analysis from Spanish Group Of Sarcoma Research (GEIS). (GEIS 38).
CTOS 2019.
Javier Martin-Broto; Nadia Hindi; Giovanni Grignani; Javier Martinez-Trufero; Andres Redondo; Claudia Valverde; Antonio López Pousa; Silvia Stacchiotti; Emanuela Palmerini; Enrique de Alava; David d. Moura; Herminia Perez-Vega; Paola Collini; Irene Otero; Patricio Ledesma; Emanuela Marchesi; Lorenzo D’Ambrosio; Jose A Lopez-Martin. IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of Sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: results of the phase II- soft-tissue sarcoma cohort. (GEIS 52).
CTOS 2019.
Josefina Cruz; Nadia Hindi; Sarah Dumont; Nicolas Penel; Pablo Luna; Enrique de Alava; Jean-Yves Blay; Silvia Stacchiotti; Paola Collini; Andres Redondo; Daniel Bernabeu; Antonio López Pousa; Giovanni Grignani; David Moura; Javier Martinez-Trufero; Philippe Terrier; Marie Karanian; Axel Le Cesne; Paolo Casali; Javier Martin-Broto. Multi-institutional european single-arm phase II trial of pazopanib in advanced Typical Solitary Fibrous Tumors (SFT). A collaborative Spanish (GEIS), Italian (ISG) and French (FSG) sarcoma groups study.
CTOS 2019.
Javier Martin-Broto; Antoine Italiano; Rosa Alvarez; Inmaculada Rincon; Javier Peinado; Paul Sargos; Ana Alvarez; Pablo Luna; Antonio López Pousa; Andres Redondo; Ignacio Alastuey; Josep Isern; Belen Belinchon; Antonio Gutierrez; Cleofe Romagosa; Marie Karanian; Carlo Morosi; Jean-Yves Blay; Alessandro Gronchi; Nadia Hindi. Trabectedin with concurrent low-dose of radiation therapy for metastatic Soft Tissue Sarcomas (TRASTS): a multicenter European, single arm phase II trial of Spanish, French and Italian sarcoma groups. (GEIS 37).
CTOS 2019.
Keith Wheatley; Veronica Moroz; Perrine Marec-Berard; Javier Martin-Broto; Hans Gelderblom; Sandra J. Strauss; Nathalie Gaspar; Jennifer Anderton; Jean-Pierre Mahieu; Ana Sastre; Valerie Laurence; Jeremy Whelan; Bernadette Brennan. First results of the Euro Ewing 2012 (EE2012) trial comparing two chemotherapy regimens in newly diagnosed Ewing Sarcoma (ES).
CTOS 2019.
Emanuela Palmerini; Marco Gambarotti; Ravin Ratan; Steven DuBois8; Michael J. Nathenson; Antoine Italiano; Enrique de Alava; Robin Jones; Salvatore Provenzano; Giovanni Grignani; Virginia Ferraresi; Rossella Bertulli; Giacomo G. Baldi; Antonella Brunello; Elisa Carretta; Elisabetta Setola; Angelo Paolo Dei Tos; Alessandra Longhi; Anna Paioli; Marilena Cesari; Michela Pierini; Uta Dirksen; Christian Rothermundt; Javier Martin-Broto; Bruno Vincenzi. GRACEFUL project: a global collaboration on CIC-DUX4, BCOR-CCNB3, high grade undifferentiated round cell sarcoma (URCS). (GEIS 72).
CTOS 2019.
Raul Teres; Ruth Orellana; Eduard Gallardo; Isidro Gracia; Ana Peiro; Jose González; Alberto Gallardo; Sandra Valverde; Jaume Llauger; Diana Hernández; Manuel Fernández; Antonio López-Pousa; Ana Sebio. Evaluation of distrofin expression by immunohistochemistry as a prognostic factor in leiomyosarcomas. GEIS 63.
CTOS 2019. Poster.
Javier Martín Broto, Nadia Hindi, Giovanni E. Grignani, Javier Martínez Trufero, Andrés Redondo, Claudia Valverde, Antonio López Pousa, Silvia Stacchiotti, Emanuela Palmerini, Enrique De Álava, David S. Moura, H. Pérez Vega, Paola Collini, Irene Otero, Patricio Ledesma, Emanuela Marchesi, Lorenzo D'Ambrosio, José A. López Martín. IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: Results of the phase II- soft-tissue sarcoma cohort. GEIS 52.
ESMO 2019.
Javier Martín Broto, Alessandro Gronchi, Nadia Hindi, Josefina Cruz, Jean-Yves Blay, Roberta Sanfilippo, Carlo Morosi, Jesús Romero, Javier Peinado, Antonio López-Pousa, Rosa Mª Álvarez Álvarez, Antoine Italiano, José Luis Pérez, Claudia Sangalli, Marie Pierre Sunyach, Cleofé Romagosa, Dominique Ranchère-Vince, Paola Collini. Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus RAdiotherapy in Soft Tissue Sarcoma patients (TRASTS). GEIS 37. Resultados Fase II cohorte A.
ESMO 2019.
D.S. Moura, P. Sanchez-Bustos, M. Lopez-Alvarez, T. Ramos, J.L. Mondaza-Hernandez, N. Hindi, J. Martin-Broto. Inhibition of mTOR signaling enhances trabectedin activity in soft tissue sarcoma. (GEIS-57).
ESMO 2019.
Josefina Cruz Jurado, Sarah Naomie Dumont, Nicolas Penel, Pablo Luna Fra, Enrique Alava, Nadia Hindi, Jean-Yves Blay, Silvia Stacchiotti, Paola Collini, Andres Redondo, Daniel Bernabeu, Antonio Lopez-Pousa, Giovanni Grignani, David Silva Moura, Javier Martinez-Trufero, Philippe Terrier, Marie Karanian, Axel Le Cesne, Paolo Giovanni Casali, Javier Martin Broto. Multi-institutional european single-arm phase II trial of pazopanib in advanced typical solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.
ASCO 2019.
Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martin Broto, Antonio Lopez Pousa, Giovanni Grignani, Antonella Brunello, Jean-Yves Blay, Robert Diaz Beveridge, Virginia Ferraresi, Iwona Lugowska, Franco Domenico Merlo, Valeria Fontana, Elena Palassini, Carlo Morosi, Silvia Stacchiotti, Angelo Paolo Dei Tos, Piero Picci, Paolo Bruzzi, Paolo Giovanni Casali. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).
ASCO 2019.
Claudia Maria Valverde Morales, Antonio Fernandez Serra, Marta Ramírez-Calvo, Jose A. Lopez-Martin, Cleofe Romagosa, Juan Antonio Carrasco, Sebastian Bauer, Javier Martinez Trufero, Josefina Cruz Jurado, Peter Reichardt, Cesar Serrano, Viktor Grünwald, Pablo Luna Fra, Oscar Persiva, Diego Varona, Rafael Morales-Barrera, Bernd Kasper, Javier Martin Broto, Amparo Ruiz-Sauri, Jose Antonio Lopez-Guerrero. Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.
ASCO 2019.
Martin G. McCabe, Veronica Moroz, Maria Khan, Uta Dirksen, Abigail Evans, Nicola Fenwick, Nathalie Gaspar, Jukka Kanerva, Thomas Kühne, Alessandra Longhi, Roberto Luksch, Cristina Mata, Marianne Phillips, Kirsten Sundby Hall, Claudia Maria Valverde Morales, Andrew J. Westwood, Mark Winstanley, Jeremy Whelan, Keith Wheatley. Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.
ASCO 2019.
Sandro Pasquali; Chiara Colombo; Sara Pizzamiglio; Paolo Verderio; Dario Callegaro; Silvia StacchiottI; Javier Martín-Broto; Antonio Lopez-Pousasup; Stefano Ferrari; Andres Povedasup; Antonino De Paoli; Vittorio Quagliuolosup; Josefina Cruz; Alessandro Comandone; Tiziana Venesio; Rita De Sanctissup; Elena Palassini; Antonio Llomboart-Bosch; Angelo P. Dei Tos; Paolo Casali; Piero Picci; Alessandro Gronchi. High-risk Undifferentiated Pleomorphic Sarcoma (UPS) treated with perioperative chemotherapy: a secondary analysis of a ISG-GEIS Randomised Clinical Trial (RCT) comparing 3 versus 5 chemotherapy cycles for high-risk Soft Tissue Sarcoma (STS).
CTOS 2018
Ana Sebio; Nadia Hindi; Josefina Cruz; Juana Maria Cano; Jeronimo Martinez-Garcia; Luis Miguel de Sande Gonzalez; Maria A. Vaz; Jordi Rubio; Jose A. Perez-Fidalgo; Javier Martín-Broto; Luis Vicioso; Isabel Sevilla. Prognostic factors in Endometrial Stromal Sarcoma (ESS): a subgroup analysis of the GEIS 26 study (Spanish group for research on sarcomas).
CTOS 2018
Bernadette Brennan; Veronica Moroz; Jennifer Anderton; Perrine Marec-Bérard; Line Claude; Javier Martin-Broto; Hans Gelderblom; Sandra Strauss; Beatrice Seddon; Jeremy Whelan; Keith Wheatley. Initial reports of local control modalities in Euro Ewng 2012: an international randomised controlled trial of chemotherapy for newly diagnosed Ewing Sarcomas (ES).
CTOS 2018
Nadia Hindi; David S. Moura; Javier Martinez-Trufero; Rosa Maria Alvarez Alvarez; Magda Conceicao; Luis Miguel de Sande Gonzalez; Gloria Marquina; Juana Maria Cano; Josefina Cruz; Claudia Valverde; Maria A. Vaz; Javier Lavernia; Antonio Lopez-Pousa; Robert Diaz Beveridge; Isabel Sevilla; Antonio Gutierrez; David Marcilla; Miguel Taron; Rafael Ramos; Javier Martín-Broto. Predictive role of HMG proteins for response to trabectedin in patients with advanced Soft Tissue Sarcoma (STS): a Spanish group for research on sarcomas (GEIS-38 study).
CTOS 2018
Silvia Stacchiotti; Stefano Ferrari; Antonio Redondo; Emanuela Palmerini; Nadia Hindi; Maria A. Vaz; Anna Maria Frezza; Antonio Gutierrez; Antonio Lopez-Pousa; Tiziana Venesio; Antoine Italiano; Sarah N. Dumont; Jean-Yves Blay; Nicolas Penel; Daniel Bernabeu; Enrique De Alava; Dominique Ranchere-Vince; Gian Paolo Dagrada; Paola Collini; Josefina Cruz; Javier Martín-Broto. Phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma. A collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.
CTOS 2018
Javier Martín-Broto; Antonio Lopez-Pousa; Nadia Hindi; Josefina Cruz; Javier Peinado; Carlo Morosi; Josep Isern Verdun; Maria Carmen Dolado; Rosa Maria Alvarez Alvarez; Ana Alvarez González; Tiziana Venesio; Marco Gattiablo Luna Fra; Ignacio Alastuey; Jean-Yves Blay; Marie-Pierre Sunyach; Inmaculada Rincon; Alessandro Gronchi; Jesus Romero. European phase I/II TRASTS Trial of trabectedin plus radiotherapy in patients with metastatic Soft Tissue Sarcoma (STS): a collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.
CTOS 2018
Javier Martin Broto, Antonio Lopez-Pousa, Nadia Hindi, Josefina Cruz, Javier Peinado, Carlo Morosi, Josep Isern, Maria Carmen Dolado, Rosa Maria Alvarez Alvarez, Ana Alvarez, Giovanni Grignani, Marco Gatti, Pablo Luna Fra, Ignacio Alastuey, Jean-Yves Blay, Marie-Pierre Sunyach, Inmaculada Rincon, Alessandro Gronchi, Jesus Romero. Multi-institutional European phase I/II trial of trabectedin plus radiotherapy in metastatic soft tissue sarcoma (STS) patients. A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.
ASCO 2018
Nadia Hindi, Rafael Ramos, Javier Martinez-Trufero, Rosa Maria Alvarez Alvarez, Magda Cordeiro, Luis Miguel Gonzalez de Sande, Gloria Marquina, Juana Maria Cano, Josefina Cruz, Claudia Maria Valverde Morales, María Ángeles Vaz Salgado, Javier Lavernia, Antonio Lopez-Pousa, Robert Diaz Beveridge, Isabel Sevilla, Antonio Gutierrez, David Marcilla, Miquel Taron, David Silva Moura, Javier Martin Broto. Prognostic role of HMG proteins in a series of 301 advanced soft tissue sarcoma patients: A Spanish Group for Sarcoma Research Study (GEIS).
ASCO 2018
Javier Martin Broto, Nadia Hindi, Andres Redondo, Javier Martinez-Trufero, Silvia Stacchiotti, Emanuela Palmerini, Enrique Alava, David Silva Moura, Herminia Perez Vega,
Irene Otero, Patricio Ledesma, Emanuela Marchesi, Jose A. Lopez-Martin. IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groupsphase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—Results of the phase I part.
ASCO 2018
Javier Martinez-Trufero, Nadia Hindi , Josefina Cruz , Rosa Alvarez, Roberto Diaz, Claudia Valverde, Antonio Gutierrez, Isabel Pajares, Antonio Lopez-Pousa, Maria Angeles Vaz, Javier Lavernia, Juana Maria Cano, Isabel Sevilla, Jordi Rubio, Ana de Juan, Juan Antonio Carrasco, Nieves Hernandez, Carolina Agra ,Lucia Ferrando, Javier Martin-Broto. New prognostic score based on growth modulation index (IGMI) in advanced soft tissue sarcomas (ASTS) treated with trabectidin (T): A Spanish group for research on sarcomas (GEIS-38 Study).
CTOS 2017
Javier Martin-Broto, David Marcilla, Rafa Ramos, David S Moura, Ramiro Alvarez, Nieves Hernandez, Carolina Agra, Empar Mayordomo, Cleofe Romagosa, Silvia Bague, Eugenia Reguero, Julia Cruz, Francisco J Martin, Antonio Gutierrez, Josefina Cruz, Rosa Alvarez, Roberto Diaz de Beveridge, Claudia Valverde, Antonio Lopez-Pousa and Javier Martinez-Trufero. Predictive role of FAS for TRABECTEDIN in second lines of advanced soft tissue sarcoma (ASTS). A Spanish Group for Research on Sarcoma (GEIS) study.
CTOS 2017
N. Hindi A. Fernandez-Serra J. Martinez-Trufero A. Carranza-Carranza A. Lopez-Pousa, J. Lavernia J.L. Arranz R. López Alegret J. Martinez-Garcia C. Valverde Morales, J.M. Cano M.A. Vaz D.S. Moura S. Bagué R. Gonzalez-Campora J.A. Lopez-GuerreroJ. Martin-Broto. Analysis of expression of immunomodulation factors in alveolar soft part sarcoma: A retrospective study from the Spanish Group for research on sarcoma.
ESMO 2017
C. Serrano,. A. Lopez Pousa, I. Pajares, C. Valverde Morales, J. Duran, J. Rubió-Casadevall, M.J. Safont, V. Martinez, R. Díaz Beveridge, A. Estival, D. Vicente Baz, A. Sebio Garcia, N. Hindi, S. Landolfi, D. Olivares, A. Garcia-Valverde, P. Ledesma, J. Arribas, J. Carles Galceran, J. Martin Broto. Clinicopathologic features and long term follow up of metastatic gastrointestinal stromal tumor (GIST) patients with durable response (>5 years) to frontline imatinib: A case control study from GEIS.
ESMO 2017
Sandro Pasquali, Chiara Colombo, Stefano Bottelli, Paolo Verderio, Javier Martin Broto, Antonio Lopez-Pousa, Stefano Ferrari, Andres Poveda, Antonino De Paoli, Vittorio Quagliuolo, Josefina Cruz, Alessandro Comandone, Giovanni Grignani, Rita De Sanctis, Elena Palassini, Antonio Llombart-Bosch, Angelo Paolo Dei Tos, Paolo Giovanni Casali, Piero Picci, Alessandro Gronchi. The sarculator stratified prognosis of patients with high-risk soft tissue sarcomas (STS) of extremities and trunk wall treated with perioperative chemotherapy in a randomized controlled trial (RCT).
ASCO 2017
Javier Martinez-Trufero, Nadia Hindi , Josefina Cruz , Rosa Alvarez, Roberto Diaz, Claudia Valverde, Antonio Gutierrez, Isabel Pajares, Antonio Lopez-Pousa, Maria Angeles Vaz, Javier Lavernia, Juana Maria Cano, Isabel Sevilla, Jordi Rubio, Ana de Juan, Maria Rodriguez, Nieves Hernandez, Carolina Agra, Javier Martin-Broto. Correlation between a new growth modulation index (GMI)-based GEISTRA score and efficacy outcomes in patients (pts) with advanced soft tissue sarcomas (ASTS) treated with trabectedin (T): A Spanish group for research on sarcomas (GEIS-38 Study).
ASCO 2017
Javier Martin-Broto, David Marcilla, Rafa Ramos, David S Moura, Ramiro Alvarez, Nieves Hernandez, Carolina Agra, Empar Mayordomo, Cleofe Romagosa, Silvia Bague, Eugenia Reguero, Julia Cruz, Francisco J Martin, Antonio Gutierrez, Josefina Cruz, Rosa Alvarez, Roberto Diaz de Beveridge, Claudia Valverde, Antonio Lopez-Pousa and Javier Martinez-Trufero. Predictive role of FAS for TRABECTEDIN in second lines of advanced soft tissue sarcoma (ASTS). A Spanish Group for Research on Sarcoma (GEIS) study.
ASCO 2017
A Gronchi, N Hindi, J Cruz, J-Y Blay, R Sanfilippo, C Morosi, J Romero, J Peinado, A Lopez-Pousa, R Alvarez, A Italiano, JL Perez, C Sangalli, MP Sunyach, C Romagosa, D Ranchere-Vince, P Collini, J Martin-Broto. Trabectedin and RAdiotherapy in Soft-Tissue Sarcoma (TRASTS) study: an international, prospective, phase I/II trial. A collaborative Spanish (GEIS), Italian (ISG) and French (CLB) group study.
ASCO 2017
Silvia Stacchiotti, Stefano Ferrari, Andres Redondo, Emanuela Palmerini, Nadia Hindi, M. Angeles Vaz, Anna Maria Frezza, Antonio Gutierrez, Antonio Lopez-Pousa, Giovanni Grignani, Antoine Italiano, Sarah Dumont, Jean-Yves Blay, Nicolas Penel, Daniel Bernabeu, Enrique de Alava, Dominique Ranchère-Vince, Paola Collini, Josefina Cruz, Javier Martin Broto. International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma. A Collaborative Spanish (GIS), Italian (ISG) and French (FSG) Sarcoma Groups Study.
ASCO 2017
Javier Martin Broto, Silvia Stacchiotti, Antonio Lopez-Pousa, Andres Redondo, Daniel Bernabeu, Paolo Giovanni Casali, Antoine Italiano, Giovanni Grignani, Sarah Dumont, Xavier Garcia del Muro, Antonio Gutierrez, Javier Martinez Trufero, Emanuela Palmerini, Nadia Hindi, Enrique de Alava, Paola Collini, Dominique Ranchère-Vince, Jean-Yves Blay, Josefina Cruz. Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT). A collaborative Spanish (GEIS), Italian(ISG) and French (FSG) sarcoma groups study.
ASCO 2017
Jaume Mora, Alicia Castaneda, Essy Madariegue, Antonio Lopez-Pousa, Claudia María Valverde, Javier Martin Broto, Xavier Garcia del Muro, Javier Martinez Trufero, Josefina Cruz, Joan Maurel, Maria Angeles Vaz, Sara Perez-Jaume, Enrique Alava, Carmen de Torres. GEIS-21: A multicentric phase II study of intensive chemotherapy including gemcitabine/docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish Group of Sarcoma Investigation (GEIS).
ASCO 2016
Claudia Valverde, Javier Martin, José Antonio López, Cleofé Romagosa, Pilar Sancho, Juan Antonio Carrasco, Andrés Poveda, Sebastian Bauer, Javier Martínez Trufero, Fina Cruz, Peter Reichardt, Pablo Luna, Viktor Grünwald, Oscar Persiva, Diego Varona, Bernd Kasper. Phase II Clinical Trial evaluating the activity and tolerability of Pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS). A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study.
ASCO 2016
Javier Martin Broto, Antonio Fernandez-Serra, Antonio Lopez-Pousa, Antonio Gutierrez, Ramon De Las Penas, Javier Martinez-Trufero, Josefina Cruz, Rosa Maria Alvarez, Ricardo Cubedo, Andres Redondo, Juan Antonio Carrasco, Jose A. Lopez-Martin, María Ángeles Sala, Isabel Sevilla, Carmen Balana, María Ángeles Vaz Salgado, Ana De Juan, Andres Poveda, Nadia Hindi, Jose Antonio Lopez-Guerrero. CUL4A and ERCC1 genes as predictive factors for trabectedin efficacy in advanced soft tissue sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) study.
ASCO 2016
Elena Palassini, Stefano Ferrari, Javier Martin Broto, Paolo Verderio, Antonio Lopez-Pousa, Angela Buonadonna, Rosalba Miceli, Silvia Stacchiotti, Angelo Paolo Dei Tos, Antonino De Paoli, Davide Maria Donati, Andres Poveda, Vittorio Quagliuolo, Alessandro Comandone, Stefano Bottelli, Piero Picci, Paolo Giovanni Casali, Alessandro Gronchi. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
ASCO 2016
J Martin-Broto, A Fernández-Serra, A Gutierrez, I Felipe, J Duran, S Calabuig, D Sanchez-Izquierdo, N Hindi, R Alemany and JA López-Guerrero. GEIS 31: Prognostic impact of COL5A2 and ACVR1B genes in intestinal high risk localized GIST. A Spanish Groups for Research on Sarcoma (GEIS) study.
ASCO 2016
Silvia Stacchiotti, Paolo Verderio, Antonella Messina, Carlo Morosi, Paola Collini, Antonio Llombart-Bosch, Javier Martin, Alessandro Comandone, Jurado Cruz, Stefano Ferrari, Giovanni Grignani, Stefano Bottelli, Vittorio Quagliuolo, Piero Picci, Antonino De Paoli, Angelo Paolo Dei Tos, Paolo G. Casali, Alessandro Gronchi, MD. Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): update at 10-year follow-up of an exploratory analysis on a Phase III trial.
ASCO 2016
Javier Martin, Elena Fumagalli, Virginia Martínez. Phase II, single-arm, non-randomized and multicenter clinical trial of regorafenib (REG) as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST. GEIS and ISG study.
GEIS 40 (REGISTRI). ASCO 2016
A. Gronchi, S. Ferrari, V. Quagliuolo, J. Martin Broto, A. Lopez-Pousa, G. Grignani, V. Ferraresi, J.-Y. Blay, P. Rutkowski, F. Merlo, E. Marchesi, P. Ledesma, A.P. Dei Tos, S. Bague Rosell, J.-M. Coindre, C. Morosi, S. Stacchiotti, P. Picci, P. Bruzzi, P. Casal. LBA6_PR - Full-dose neoadjuvant anthracycline+ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial.
Oral. Presidential Sympossium. ESMO 2016 Copenhague
N. Hindi; J. Martinez-Trufero; A. Carranza; A. Lopez-Pousa; R. Alvarez; J.L. Arranz; J. Martinez; C. Valverde; J.M. Cano; C. Tous; R. Ribas; R. Gonzalez-Campora; J. Martin-Broto. Exploratory analysis of immunomodulation and apoptosis factors in alveolar soft-part sarcoma: a retrospective study from the Spanish Group for Research on Sarcoma (GEIS).
Oral. CTOS 2016
J. Martin-Broto; M. Mendiola; L. Guerra; A. Gutierrez; I. Felipe; J. Martinez-Trufero; L.M. de Sande Gonzalez; N. Hindi; C. Tous; C. Valverde; A. Casado; R. Ramos; V. Martinez-Marin. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine/ docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish Group of Sarcoma Investigation (GEIS).
Oral. CTOS 2016
Jaume Mora, MD, PhD; Alicia Castañeda; Antonio Lopez-Pousa; Claudia Valverde; Javier Martin-Broto; Xavier Garcia del Muro; Enrique de Alava; Carmen de Torres. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine/ docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish Group of Sarcoma Investigation (GEIS).
Póster. CTOS 2016
Nadia Hindi, MD; Pablo Luna; Antonio Lopez-Pousa; Jordi Rubio; Claudia Valverde; Javier Martinez-Trufero; Jeronimo Martinez; Maria Angeles Sala; Juan Luis Arranz; Fatima Toscano; Rosa Alvarez; Juana Maria Cano; Nuria Lainez; Ana de Juan; Javier Martin-Broto. Phase II trial of gemcitabine plus rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study.
Póster. CTOS 2016
Javier Martin Broto, Andrés Redondo, Claudia María Valverde, María Ángeles Vaz Salgado, Jaume Mora, Xavier Garcia del Muro, Maria Pilar Sancho Marquez, Javier Martinez-Trufero, Robert Diaz Beveridge, Antonio Gutierrez, Pilar Blay, Cristina Tous, Pablo Luna Fra, Antonio Lopez-Pousa. Phase II trial of gemcitabine plus rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study.
ASCO 2015
Javier Martin Broto, Antonio Fernandez-Serra, Jose Duran, Silvia Calabuig-Fariñas, Antonio Gutierrez, Irene Felipe-Abrio, Dolors Sanchez-Izquierdo, Javier Martinez-Trufero, Antonio Casado Herraez, Andres Poveda, Luis Rubio Martinez, Carmen Balana, Ferran Losa, Claudia María Valverde, Jordi Rubió, Josefina Cruz, Luis Miguel Gonzalez de Sande, Cristina Tous, Ricardo Cubedo, Jose Antonio Lopez-Guerrero. Prognostic relevance of miRNA let-7e in localized intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study.
ASCO 2015
Josefina Cruz, Nadia Hindi, Rosa Alvarez, Jose Antonio López, Antonio Gutierrez, Antonio Lopez-Pousa, Maria Jesús Blanco, Javier Martinez-Trufero, Juana Maria Cano, Claudia Valverde, Jerónimo Martínez, Jordi Rubió, Angeles Sala, J Alejandro Perez-Fidalgo, Javier Martin. Visceral angiosarcoma series: differential behaviour between breast angiosarcomas and other locations. A Spanish Group for Sarcoma research (GEIS) study.
CTOS 2015 St Lake City
Josefina Cruz, Nadia Hindi, Rosa Alvarez, Jose Antonio López, Antonio Gutierrez, Antonio Lopez-Pousa, Maria Jesús Blanco, Javier Martinez-Trufero, Juana Maria Cano, Claudia Valverde, Javier Lavernia, Maria Angeles Vaz, Isabel Sevilla, Luis Miguel de Sande Gonzalez, Javier Martin. Somatic localized angiosarcoma: a clinico-pathological series characterization from the Spanish Group for sarcoma research (GEIS).
CTOS 2015 St Lake City
Nadia Hindi, Josefina Cruz, Rosa Álvarez, Juana María Cano, Antonio Gutierrez, Jerónimo Martínez, Antonio Lopez-Pousa, Jose Antonio López, Pablo Luna, Luis Maríz González de Sande, Maria Jesús Blando, Javier Lavernia, Salmvador Martín-Algarra, Javier Martinez-Trufero, Javier Martin. Epithelioide hemangioendotelioma: a retrospective analysis from the spanish Group for sarcoma research (GEIS).
CTOS 2015 St Lake City
Martin Broto J. Prognostic relevance of fas ligand (fasl) in advanced sarcomas. Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin vs doxorubicin. A GEIS study.
CTOS 2014
Martín Broto J. Integrating genotype in risk classification for gist recurrence. A Spanish Group for Sarcoma Research (GEIS) Study.
ESMO 2014
Maurel J. Prognosis of p-IGF-1R and MMP3 expression in advanced GIST patients treated with imatinib. A GEIS study.
ESMO 2014
Cruz F. Solitary Fibrous Tumor (SFT): A registry program (RP) to assess frequency and Management in our country. A Spanish Group for Research on Sarcoma (GEIS) study.
ESMO 2014
Martínez Trufero J. Multidisciplinary treatment outcome of desmoid-type fibromatosis (DTF). A registry-based study from Spanish Group for Research on Sarcoma (GEIS).
ESMO 2014
Garcia del Muro X, López Pousa A, Martínez Trufero J, Martín Broto J, Cubedo R, Lavernia J, Redondo A, López Martín JA, Mulet N, Sanjuan X, Martinez Tirado. O Phase II study of gemcitabine (GEM) plus sirolimus (SIR) in previously treated patients with advanced soft tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.
J Clin Oncol 32:5s, 2014 (suppl; abstr 10594) ASCO 2014
Martin Broto J, MArtínez Serra J, Ramos R, López Guerrero JA, Bagué S, Martínez C, Álvarez R, García del Muro X, de las Peñas R, Gutiérrez A, Martínez Trufero J, Cruz J, Poveda A, Álvarez R, Cubedo R, Redondo A, Maurel J, Sala MA, López Martín JA, López Pousa. A Prognostic/predictive biomarkers in advanced soft tissue sarcomas (STS): Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin versus doxorubicin—A GEIS study.
Oral Abstract Session, Sarcoma. J Clin Oncol 32:5s, 2014 (suppl; abstr 10500) ASCO 2014
Martin Broto J, Redondo A, Martínez Trufero J, Valverde C, Vaz, MA, Medina J, Obrador A, Felipe I, Castelo B, Hidalgo P, Pajares I, Duran J, Amurrio R, Alemany R. Nilotinib as co-adjuvant treatment with doxorubicin in sarcomas: Phase I trial results—A Spanish Group for Research on Sarcoma (GEIS) study.
J Clin Oncol 32:5s, 2014 (suppl; abstr 10573). ASCO 2014
P Giovanni Casali, A Le Cesne, A Poveda Velasco, D Kotasek, P Rutkowski, P Hohenberger, E Fumagalli, I Robert Judson, A Italiano, J Martin Broto, A Gronchi, A Paolo Dei Tos, S Marreaud, W T.A. Van Der Graaf, J Raymond Zalcberg, S Litière, JY Blay and EORTC Soft Tissue and Bone Sarcoma Group (EORTC STBSG), French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Grupo Español de Investigación en Sarcomas (GEIS), Australasian Gastro-Intestinal Trials Group (AGITG). Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial.
Poster discussion: Proc Am Soc Clin Oncol. 2013:31;10500
Garcia del Muro, Joan Maurel, Javier Martinez Trufero, Javier Lavernia, A Lopez-Pousa, R De Las Penas, R Cubedo, J Fra, A Casado, A De Juan, L Jimenez Colomo and J Martin Broto. Phase II trial of ifosfamide in combination with sorafenib in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol. 2013:31;10523.
J Martin Broto, R Ramos, J Martinez-Trufero, S Calabuig, C Horndler, A Casado, L Ortega, LM Gonzalez de Sande, F Izquierdo, A Gutierrez, A Sala, A Ugalde, C Valverde, I de Torres, F Losa, Remei Blanco, R Sanchez Gomez, R Cubedo, JA Carrasco, C Balañá and Spanish Group for Research on Sarcomas (GEIS). Prognostic significance of Wnt signaling pathway molecules in nongastric GIST patients: A tissue microarray-based (TMA) analysis.
Poster discussion: Proc Am Soc Clin Oncol. 2013:31;10529.
J. Martin Broto, X. Garcia Del Muro, A. Lopez-Pousa, R. De Las Penas, J. Maurel, R. Cubedo5, A. Redondo, J. Martinez-Trufero, J. Cruz Jurado, A.M. Poveda. Randomized, open, prospective, phase II clinical trial of doxorubicin (Doxo) vs. trabectedin plus Doxo in the first-line treatment of patients (pts) with advanced non-operable and/or metastatic soft tissue sarcomas (STS): GEIS-20 study.
ESMO 2012, 1517.
J Martin Liberal, M Gil, L Jimenez, M Ochoa de Olza, C Munoz, N Gonzalo, R Rigo, H Colom, M Sainz Jaspeado, O M. Tirado and X Garcia del Muro. Phase I study of sirolimus plus gemcitabine in patients with advanced solid tumors: A Spanish Group for Research on Sarcomas (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol. 2012:30;3096.
X Garcia del Muro, A Lopez-Pousa, MJ Flor, A Redondo, J Cruz Jurado, R Andres, A Casado, J Fra, JA Lopez-Martin, J Maurel, C Valverde, O Gallego, JA Narvaez, S Bague, X Sanjuan and JM Vinyals. Phase II study of neoadjuvant high-dose ifosfamide with concurrent radiotherapy followed by surgical resection in high-risk soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol. 2012:30;10052.
J Martin Broto, A Lopez-Pousa, R Ramos, A Gronchi, P Giovanni Casali, A Gutierrez, Piero Picci, S Ferrari, Josefina Cruz, P Luna Fra, Antonio Casado, R Cubedo, R Lasso, Andres Poveda, A De Juan, C Balana, S Calabuig, A Obrador and J Antonio Lopez-Guerrero. Relationship of CUL4A gene underexpression and prognosis in localized high-risk soft tissue sarcoma (STS) patients of limbs or trunk wall.
Poster discussion: Proc Am Soc Clin Oncol. 2012:30;10079.
P.G. Casali, S. Stacchiotti, P. Verderio, P. Collini, A. P. Dei Tos, M. Alberghini, A. Llombart-Bosch, C. Morosi, A. Messina, M. Mercuri and A. Gronchi. Histology and outcome in localized high-risk soft tissue sarcomas (STS) treated with preoperative chemotherapy (CHT) with or without radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS).
Poster discussion: Proc Am Soc Clin Oncol. 2011:29;10089.
S. Stacchiotti, P. Verderio, A. Messina, C. Morosi, A. Ferraro, V. Quagliuolo, J. Martin, A. Comandone, G. Grignani, P. Picci, S. Frustaci, A. Gronchi and P. G. Casali. Tumor response and outcome in localized high-risk soft tissue sarcomas (STS) treated with preoperative chemotherapy (CHT) with or without radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS).
Poster discussion: Proc Am Soc Clin Oncol 2011:29;10019.
J. Rubió, J. Martinez-Trufero, A. Lopez-Pousa, X. Garcia del Muro, J. Fra, A. Redondo, N. Lainez, A. Poveda, A. Casado, C. M. Valverde, A. De Juan, I. Sevilla, R. Andres, J. Cruz, M. J. Safont, J. Martin Broto, X. Garcia-Albeniz and J. Maurel. Retrospective analysis of surgery in metastatic GIST patients sensitive to imatinib: A Spanish Group for Research on Sarcoma (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol 2011:29;10055.
J. Martin Broto, X. Garcia del Muro, A. Gutierrez, J. Martinez-Trufero, T. Serrano, J. Rubió, N. Lainez, I. Sevilla, J. Cruz, R. Ramos, L. Ortega, A. Poveda, M. Ramirez, R. Cubedo, J. Lopez-Guerrero and Spanish Group for Sarcoma Research (GEIS). KIT, DOG1, PDGFR, and IGFR1 gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.
Poster discussion: Proc Am Soc Clin Oncol 2011:29;10047.
Lopez-Pousa, B. Bui Nguyen, X. Garcia del Muro, J. Martin Broto, C. Balañá, J. Lavernia, J. Cruz, J. Maurel, R. Andres, C. M. Valverde, J. Fra, J. Martinez-Trufero, J. A. Lopez-Martin, I. Sevilla, R. Cubedo and J. Blay. A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.
Poster discussion: Proc Am Soc Clin Oncol 2011:29;10072.
J. Martin Broto, X. Garcia del Muro, J. Rubio, A. Gutierrez, J. Martinez-Trufero, I. Sevilla, N. Lainez, R. Andres, R. Ramos and J. A. Lopez-Guerrero. Prognostic factors of KIT-negative GIST-like patients (KNGL): A Spanish Group for Sarcoma Research (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol 2010:28;10070.
X. Garcia del Muro, A. Lopez-Pousa, J. Martin Broto, R. Cubedo, L. Jimenez Colomo, O. Gallego and M. Provencio-Pulla. Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol 2010:28;10024.
Gronchi, S. Frustaci, M. Mercuri, J. Martin Broto, A. Lopez-Pousa, L. Mariani, P. Verderio, V. Quagliuolo, P. G. Casali and P. Picci. Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: Three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: A phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS).
Poster discussion: Proc Am Soc Clin Oncol 2010:28;10003.
X. Garcia Del Muro, J. Fra, A. Lopez Pousa, J. Maurel, J. Martín, J. Martínez Trufero, A. Casado, J. Cruz, M. A. Gómez España and J. Lavernia. Randomized phase II study of dacarbazine plus gemcitabine versus DTIC alone in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol 2009:26;10529.
D. Fuster, A. Sierra, J. R. Ayuso, A. Poveda, R. Cubedo, A. Casado, J. Martínez-Trufero, A. López-Pousa, X. Garcia Del Muro and J. Maurel. Correlation between spiral CT and PET in patients with advanced GIST refractory to high-dose imatinib: A GEIS study.
Poster discussion: Proc Am Soc Clin Oncol2009:27;10553.
A Lopez Pousa; J. Martin; C. Balaña; A. Poveda; J. Garcia del Muro; J. Maurel; R. Cubedo. Phase I-II study of a new formulation of non-pegylated liposomal doxorubicin (doxo Gp-pharm) as first-line treatment of older patients with advanced soft-tissue sarcomas (STS): a GEIS study. Spanish Group for Research in Sarcomas, Geis, Spain.
14th CTOS Annual Scientific Meeting, London, November 2008; 35129.
Poveda, J. Maurel, R. Cubedo, A. Casado, J. Ayuso, D. Fuster, J. Martinez-Trufero, A. Lopez-Pousa, J. Martin and X. Garcia del Muro. Phase I-II trial of imatinib (IM) and low-dose doxorubicin (DX) in patients (pts) with advanced gastrointestinal stromal tumors (GIST), refractory to high-dose IM: A GEIS Study.
Poster discussion: Proc Am Soc Clin Oncol 2008:26;10520.
J. Maurel, A. Lopez-Pousa, R. de las Peñas, J. Fra, J. Cruz, J. Martin, A. Casado, J. Martinez-Trufero, A. Poveda and X. Garcia del Muro. Standard-dose doxorubicin versus sequential dose-dense doxorubicin and ifosfamide in patients with untreated advanced soft tissue sarcoma (ASTS): A GEIS Study.
Poster discussion: Proc Am Soc Clin Oncol 2008:26;10570.
J. Martin, A. Gutierrez, J. Garcia del Muro, J. Maurel, L. M. Gonzalez de Sande, J. Martinez, A. De Juan, N. Lainez, F. Losa and A. Poveda. Time dependence of critical deletions as prognostic factor for relapse-free survival (RFS) in localised GIST. A Spanish Group for Sarcoma Research (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol 2008:25;10508.
Romero, A. Poveda, J. Martin, A. Lopez-Pousa, C. Gomez, M. Safont, R. Andres, V. Guillem, A. Llombart-Bosch and J. Lopez-Guerrero. Pathological significance of deletions involving codons 557 and 558 of KIT gene in localized resected gastrointestinal stromal tumors (GIST) of intermediate and high risk: A study by the Spanish Group for Sarcoma Research (GEIS).
Poster discussion: Proc Am Soc Clin Oncol 2007:25;10051.
García del Muro X, Poveda A, Buesa JM, Martínez-Trufero J, González de Sande LM, Calvo E, Escudero P, López-Pousa A, Fabregat X, Casado A. Phase II Trial of Temozolomide as First-line Treatment for Patients with Advanced Gynecological Sarcoma: A Spanish Group for Research on Sarcomas (GEIS) and Spanish Ovarian Cancer Research Group (GEICO) Study.
Poster Discussion. Proc Am Soc Clin Oncol 2006 juny Atlanta.
García del Muro X, Fra F, Martínez-Trufero J, Sevilla I, Escudero P, Cruz J, Martín J, Casado A, Arrazubi V, Buesa JM. Temozolomide in the treatment of gynecological leiomyosarcoma: A Spanish Group for Resarch in Sarcomas (GEIS) study.
Poster Discussion. Proc Am Soc Clin Oncol 2005;22:9030.
López-Pousa A, Buesa JM, Casado A, García del Muro X, Poveda A, Maurel J, Martín J, Balañá C, Martínez-Trufero J, Martín J, Poveda A, Llombart-Bosch A, Ramos R, García del Muro X, Martínez-Trufero J. Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Resarch in Sarcomas (GEIS).
General Poster Session. Proc Am Soc Clin Oncol 2004;22:9033.
Martín J, Poveda A, Llombart-Bosch A, Ramos R, García del Muro X, Martínez-Trufero J, de Juan A, Maurel J, Losa F, Buesa JM. Prognostic value of pathologic variables and mutations type in patients with complete surgical resection of gastrointestinal stromal tumors (GIST). A GEIS study.
General Poster Session. Proc Am Soc Clin Oncol 2004;22:9029.
Buesa JM, Fra J, López-Pousa A, Losa R, Mareque B, Sierra M, Una E, Blay P. Phase I trial of Dacarbacine (DTIC) and prolonged infusion Gemcitabine in patients with soft Tissue sarcoma.
Poster Discussion. Proc Am Soc Clin Oncol vol 2003;22:3296.
López-Pousa A, Buesa JM, Martín J, Casado A, Balañá C, García del Muro X, Poveda A. Phase I/II trial of Doxorubicin and dose escalation prolonged infusion Gemcitabine as first line treatment in advanced soft tissue sarcomas. A study of the Spanish Group for Research in Sarcomas (GEIS).
General Poster Session. Proc. Am Soc Clin Oncol 2003; 22(825):3317.
Martín J, López-Pousa A, Bover I, Sevilla I, Cruz J, Buesa JM, Escudero P, Blanco R, Poveda A, Casado A, García del Muro X, Maurel J, Piera JM, Maestu I, Casado S, Carles J, González de Sande LM, Montalar J, Martínez-Trufero J, de las Peñas R, Rifa J. Malignant Gastointestinal stromal tumors and uterine sarcomas: differences in prognostic factors for survival. A clinical approach. Study of the Spanish Group for Research in sarcomas (GEIS).
Poster Discussion. Proc Am Soc Clin Oncol 2002;21(411ª):a-1641.
Buesa JM, Teijido PG, Fra J, et al. Treatment of ifosfamide (IFOS) encephalopathy with intravenous thiamine.
Poster Discussion. Proc Am Soc Clin Oncol 2002;21:409,a.
Maurel J, Buesa JM, López-Pousa A, García del Muro X, Martínez-Trufero J, de las Peñas R, Escudero P, Piera JM, Martín J, Casado A, Sevilla I, Balañá C, Bover I, Montalar J, Poveda A, Cassinello J, Cruz J, Carles J, Camps C, Bellmunt J. High-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma patients. An analysis of prognostic factors: A study of the Spanish Group for Research on Sarcomas (GEIS).
Proc Am Soc Clin Oncol 2002;21(407ª):a-1627.
García del Muro X, López-Pousa A, Buesa JM, Martín J, Poveda A, Bover I, Escudero P, Martínez-Trufero J, Casado A. Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcoma: A phase II trial of the Spanish Group for Research on Sarcomas (GEIS).
2001 CTOS Annual Meeting Posters— Medical Oncology.
García del Muro X, López-Pousa A, Buesa JM, Martín J, Poveda A, Bover I, Escudero P, Martínez-Trufero J, Casado A. Temozolomide as a 6 week continuous oral schedule in advanced soft tissue sarcomas: A phase II study of the Spanish Group for Research on Sarcomas (GEIS).
Proc. Am Soc Clin Oncol 2001; 20: 1412.
López-Pousa A, Buesa JM, García del Muro X, et al. Sequential high-dose doxorubicin (Dx) and High dose Ifosfamide (IF) in advanced previosly untreated soft tissue sarcoma of the adult (STS). A multicenter phase II study of the Spanish Group for Research on Sarcomas (GEIS).
Proc Am Soc Clin Oncol 2001;20:353.
García del Muro X, López-Pousa A, Buesa JM, Martín J, Bover I, Escudero P, Casado A, Martínez-Trufero J, Maurel J. Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcomas: a phase II study of the Spanish Group for Reseach in Sarcomas (GEIS).
Poster – Discussion. 37th ASCO Annual Meeting. San Francisco, mayo 2001. Proc Am Soc Clin Oncol 2001;20:354a.
López-Pousa A, Buesa JM, García del Muro X, Manuel J, Balañá C, Casado A, Bellmunt J, Poveda A, Martín J, Martínez-Trufero J, de las Peñas R, Bover I. Sequential High-dose Doxorubicin and High-dose Ifosfamide in advanced previously untreated soft tissue sarcomas of the adult. A multicenter phase II study of the Spanish Group for Reseach in Sarcomas (GEIS).
Poster – Discussion. 37th ASCO Annual Meeting. San Francisco, mayo 2001. Proc Am Soc Clin Oncol 2001;20:353a
López-Pousa A, Buesa JM, Montalar J, Martín J, Maurel J, García del Muro X, de las Peñas R, Cruz J, Cassinello J, Sevilla I, Balañá C, Casado A. First-line Doxorubicin and scalated High-dose Ifosfamide in advanced soft tissue sarcoma patients a phase II study of the Spanish Group for Research in Sarcomas (GEIS).
Comunicación-Poster- Sesion. 36th ASCO New Orleans, Louisiana, mayo 2000.
Buesa JM, Teijido PG, Galbe M, López-Pousa A, García del Muro X; Martín J, Antón A, Montalar J, de las Peñas R, Cruz J, Escudero P, Fra J, Menéndez D, Poveda A. Nephrotoxicity of continuous infusion ifosfamide. A study of the Spanish Group for Research on Sarcomas (GEIS)”.
Abstract 0037. 5th CTOS congress. Arlington, Octubre 1999.
Poveda A, López-Pousa A, Martín J, Buesa JM, Balañá C, Menéndez D. Liposomal Doxorubicin (Caelyx) in advanced soft tissue sarcoma patients. A phase II study of the Spanish Group for Research in Sarcomas (GEIS).
Comunicación. 36th ASCO. Atlanta, mayo 1999. Proc Am Soc Clin Oncol 1999;18:553a.
López-Pousa A, Buesa JM, Montalar J, Martín J, Maurel J, García del Muro X, de las Peñas R, Cruz J, Cassinello J, Sevilla I, Balañá C, Casado A, Bover I, Paredes A, Carles J, Poveda A. Phase II trial of Doxorubicin and High-dose Ifosfamide in advanced previously untreated soft tissue sarcoma patients. a study of the Spanish Group for Research in Sarcomas (GEIS).
Poster Discussion. 36th ASCO. Atlanta, mayo 1999. Proc Am Soc Clin Oncol 1999;18:544a.
López-Pousa A, Montalar J, Buesa JM, Maurel J, Martín J, Cassinello J; Sevilla I; de las Peñas R, Cruz J, Balañá C. First-line doxorubicin and high-dose ifosfamide (DHI) in advanced soft tissue sarcoma (STS) patients. A phase II study of the Spanish Group for Research on Sarcomas.
Abstract 564. 23rd ESMO Congress. Atenas, Noviembre 1998.
López-Pousa A, Montalar J, Buesa JM, Maurel J, Martín J, Cassinello J, Sevilla I, de las Peñas R, Cruz J, Balañá C, García del Muro X, Poveda A. High-Dose Ifosfamide and Doxorubicin in advanced previously untreated soft tissue sarcoma patients. a phase II study of the Spanish Group for Research in Sarcomas (GEIS).
4th CTOS Annual Scientific Meeting. Vancouver, November 1998.
Buesa JM, López-Pousa A, Antón A, Martín J, García del Muro X, Bellmunt J, Poveda A, Escudero P. Phase II trial of first–line high-dose Ifosfamide in advanced soft tissue sarcoma (STS) patients.
Poster. 33nd ASCO. Denver, Mayo 1997. Proc Am Soc Clin Oncol 1997;16:498a.